secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-07-01T20:01:16+00:00
Accession:  0001193125-26-292501
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 4.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics files Chapter 11; stock now trades on OTCID Basic under SGMOQ; auditor EY terminated
--------------------------------------------------------------------------------

- Filed voluntary Chapter 11 petition (Case No. 26-10989) on June 24, 2026.
- Common stock began trading on OTCID Basic Market under symbol SGMOQ on June 24, 2026.
- Nasdaq delisting appeal pending; stock suspended from Nasdaq since May 5, 2026.
- Audit committee terminated Ernst & Young as independent auditor on June 25, 2026.
- No new auditor engaged; EY's reports included going-concern explanatory paragraph.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526292501/0001193125-26-292501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526292501/d113173d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-292501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer